GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » American Cryostem Corp (OTCPK:CRYO) » Definitions » Total Liabilities

American Cryostem (American Cryostem) Total Liabilities : $2.94 Mil (As of Jun. 2022)


View and export this data going back to 2010. Start your Free Trial

What is American Cryostem Total Liabilities?

American Cryostem's Total Liabilities for the quarter that ended in Jun. 2022 was $2.94 Mil.

American Cryostem's quarterly Total Liabilities increased from Dec. 2021 ($2.57 Mil) to Mar. 2022 ($2.93 Mil) and increased from Mar. 2022 ($2.93 Mil) to Jun. 2022 ($2.94 Mil).

American Cryostem's annual Total Liabilities declined from Sep. 2019 ($2.53 Mil) to Sep. 2020 ($1.90 Mil) but then increased from Sep. 2020 ($1.90 Mil) to Sep. 2021 ($2.90 Mil).


American Cryostem Total Liabilities Historical Data

The historical data trend for American Cryostem's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

American Cryostem Total Liabilities Chart

American Cryostem Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.03 1.97 2.53 1.90 2.90

American Cryostem Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.39 2.90 2.57 2.93 2.94

American Cryostem Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

American Cryostem's Total Liabilities for the fiscal year that ended in Sep. 2021 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.631+(0.293+0.98
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=2.90

Total Liabilities=Total Assets (A: Sep. 2021 )-Total Equity (A: Sep. 2021 )
=1.056--1.848
=2.90

American Cryostem's Total Liabilities for the quarter that ended in Jun. 2022 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.545+(0.151+1.239
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=2.94

Total Liabilities=Total Assets (Q: Jun. 2022 )-Total Equity (Q: Jun. 2022 )
=1.058--1.876
=2.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


American Cryostem Total Liabilities Related Terms

Thank you for viewing the detailed overview of American Cryostem's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


American Cryostem (American Cryostem) Business Description

Traded in Other Exchanges
N/A
Address
1 Meridian Road, Suite 5, Eatontown, NJ, USA, 07724
American Cryostem Corp is a biotechnology company which standardizes adipose tissue-derived technologies (Adult Stem Cells) for the fields of Regenerative and Personalized Medicine. The company acts as an innovator of adipose tissue and stem cell platform technologies. It provides the clinical grade, adipose tissue and adult stem cell collection, processing, and cryo-preservation technology, providing first-in-class cellular therapy products and services for patients, physicians and researchers based on the transformative science of Regenerative and Personalized Medicine.
Executives
John S Arnone director, officer: Chairman 111 GREAT NECK RD, GREAT NECK NY 11021
Anthony Francis Dudzinski director, officer: COO 188 EAST BERGEN PLACE, SUITE 204, RED BANK NJ 07701
Acs Global, Inc. 10 percent owner 188 E. BERGEN PLACE, SUITE 204, RED BANK NJ 07701
Christopher Joseph Neill 10 percent owner 188 EAST BERGEN PLACE, SUITE 204, RED BANK NJ 07701
Hector Medina director, 10 percent owner, officer: President and Director 1206 STAGECOACH TRAIL LOOP, CHULA VISTA CA 91915